Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Daiichi Sankyo Co Ltd's Subsidiary Submits NDA for Cell-Based Pandemic Flu Vaccine- Pharma Japan


Sunday, 30 Jun 2013 08:00pm EDT 

Pharma Japan reported that Daiichi Sankyo Co Ltd announced that its subsidiary Kitasato Daiichi Sankyo Vaccine has filed a new drug application (NDA) on June 19, 2013 for the cell-based pandemic influenza vaccine. 

Company Quote

1702.5
-1.0 -0.06%
26 Dec 2014